Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects

被引:1
|
作者
Wang, Meng [1 ]
Zhou, Wenjia [1 ]
Zhang, Quanying [1 ]
Zong, Shunlin [1 ]
Lv, Chengzhe [2 ]
机构
[1] Soochow Univ, Clin Pharmacol Lab, Affiliated Hosp 2, Suzhou City, Jiangsu, Peoples R China
[2] Soochow Univ, Dept Pharmaceut, Childrens Hosp, Suzhou City, Jiangsu, Peoples R China
来源
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | 2020年 / 9卷 / 05期
关键词
rasagiline transdermal patch; pharmacokinetics; pharmacodynamics; safety; single dose; multiple dose; PARKINSON-DISEASE; MAO-B; INHIBITOR; PATHOGENESIS;
D O I
10.1002/cpdd.761
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A rasagiline transdermal patch can be used to offer continuous rasagiline to patients with Parkinson's disease who cannot take their usual oral medications. This was the first study to investigate the pharmacokinetics, pharmacodynamics, and safety of the rasagiline transdermal patch in healthy Chinese subjects. Thirty subjects were randomized to 3 groups with 10 subjects in each group. The 10 subjects of group 1 received a single 1-mg dose of rasagiline as a tablet; the 20 subjects of groups 2 and 3 received a single transdermal patch (48-hour patch-on period) containing 1.25 mg and 2.5 mg rasagiline, respectively. After a 2-week washout period, the subjects of group 1 were assigned to receive 1 mg of rasagiline tablets every 24 hours for 7 days, and the subjects of group 2 were assigned to receive 1.25-mg rasagiline transdermal patches (48-hour patch-on period) every 72 hours for 5 time periods. The absorption of rasagiline from the transdermal patch was significantly improved, although the peak plasma concentration was obviously reduced. There was slight accumulation of rasagiline dose after multiple administrations. Inhibition of platelet monoamine oxidase-B (MAO-B) activity was dose dependent. The 80% inhibition maintained for at least 48 hours after multiple-dose administration of 1 mg tablets, and for 72 hours after multiple-dose administration of 1.25 mg/48 h patch. Compared with rasagiline tablets, the transdermal patch had a prolonged duration of 80% inhibition and increased maximal inhibition of MAO-B activity. These characteristics permitted an interval of 3 days of dosing, which was convenient for patients to use.
引用
收藏
页码:602 / 609
页数:8
相关论文
共 50 条
  • [31] Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects
    Yue-Qi Li
    Zheng-Yu Yan
    Hong-Wen Zhang
    Lu-Ning Sun
    Hui-Wen Jiao
    Mei-Feng Wang
    Li-Yuan Yu
    Lei Yu
    Zi-Qing-Yun Yuan
    Ling Meng
    Yong-Qing Wang
    European Journal of Clinical Pharmacology, 2017, 73 : 547 - 554
  • [32] Tolerability and Pharmacokinetics of Single Escalating and Repeated Doses of CN-105 in Healthy Participants
    Li, Shuya
    Wangqin, Runqi
    Meng, Xia
    Li, Hao
    Wang, Yi
    Wang, Haichen
    Laskowitz, Daniel
    Chen, Xia
    Wang, Yongjun
    CLINICAL THERAPEUTICS, 2022, 44 (05) : 744 - 754
  • [33] Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects
    Li, Yue-Qi
    Yan, Zheng-Yu
    Zhang, Hong-Wen
    Sun, Lu-Ning
    Jiao, Hui-Wen
    Wang, Mei-Feng
    Yu, Li-Yuan
    Yu, Lei
    Yuan, Zi-Qing-Yun
    Meng, Ling
    Wang, Yong-Qing
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (05) : 547 - 554
  • [34] Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects
    Dvorchik, BH
    Brazier, D
    DeBruin, MF
    Arbeit, RD
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) : 1318 - 1323
  • [35] Orally administered TQ-A3334 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics single and multiple ascending doses in healthy Chinese subjects
    Hu, Yue
    Zhang, Hong
    Wu, Min
    Huo, Dandan
    Chen, Hong
    Li, Xiaojiao
    Xu, Zhongnan
    Ding, Yanhua
    Niu, Junqi
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E466 - E467
  • [36] Eslicarbazepine acetate pharmacokinetics after single and repeated doses in healthy subjects
    Vaz-da-Silva, M
    Nunes, T
    Soares, E
    Rocha, JF
    Tavares, S
    Falcao, A
    Almeida, L
    Soares-da-Silva, P
    EPILEPSIA, 2005, 46 : 191 - 191
  • [37] Multiple-dose applications of rotigotine transdermal patch to evaluate the pharmacokinetics, safety, and tolerability in healthy subjects.
    Kim, B. H.
    Lim, K. S.
    Kim, J. W.
    Kim, M. G.
    Kim, T. E.
    Chung, Y. J.
    Yu, K. S.
    Shin, S. G.
    Jang, I. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S25 - S26
  • [38] Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses
    Wang, Hongyun
    Ou, Ning
    Lang, Liwei
    Shi, Ruihua
    Hu, Pei
    Jiang, Ji
    XENOBIOTICA, 2016, 46 (12) : 1133 - 1141
  • [39] Safety, tolerability, pharmacokinetics (PK) / pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP-1 analogue, in healthy male subjects
    Kapitza, C.
    Lynge, J.
    Duering, M.
    Jensen, C.
    DIABETOLOGIA, 2012, 55 : S341 - S341
  • [40] Safety, Pharmacokinetics/Pharmacodynamics, and Absolute Bioavailability of Dexmedetomidine Hydrochloride Nasal Spray in Healthy Subjects: A Randomized, Parallel, Escalating Dose Study
    Kuang, Yun
    Wang, Sai-Ying
    Wang, Meng-Na
    Yang, Guo-Ping
    Guo, Can
    Yang, Shuang
    Zhang, Xing-Fei
    Yang, Xiao-Yan
    Pei, Qi
    Zou, Chan
    He, Yan-Hong
    Zhou, Ying-Yong
    Duan, Kai-Ming
    Huang, Jie
    FRONTIERS IN PHARMACOLOGY, 2022, 13